Viking Therapeutics, Inc. (VKTX)

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Headquarters: San Diego, CA · Employees: 59 · Website: https://www.vikingtherapeutics.com

Supply-chain relationships for VKTX

• PIPER SANDLER COMPANIES (PIPR) — supplier

Frequently asked questions about Viking Therapeutics, Inc. (VKTX)

What is Viking Therapeutics, Inc. (VKTX)?

Viking Therapeutics, Inc. (VKTX) is a publicly traded company in the Pharmaceutical Preparations sector (Biotechnology), listed on Nasdaq. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.

Who are Viking Therapeutics, Inc.'s key suppliers and customers?

Macroplane tracks Viking Therapeutics, Inc.'s (VKTX) supply chain. Key suppliers include PIPER SANDLER COMPANIES (PIPR).